CeNeS Pre-clinical Candidate rhGGF2 Cited as Potential Treatment for Schizophrenia
May 14, 2002 02:37 ET
|
CeNeS Pharmaceuticals Plc
CAMBRIDGE, U.K., May 14, 2002 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) today noted recent press coverage on the identification of a risk gene for schizophrenia that has implications for its...
CeNeS Announces the Termination of Bioglan Drug Delivery Agreements
April 02, 2002 04:24 ET
|
CeNeS Pharmaceuticals Plc
CAMBRIDGE, U.K., April 2, 2002 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) announced today that it had agreed with the administrators of Bioglan Pharma plc (LSE:BGP), the termination of their...
CeNeS Announces Preliminary Results for the Year- Ended December 31, 2001 (with link)
March 27, 2002 03:16 ET
|
CeNeS Pharmaceuticals Plc
CAMBRIDGE, U.K., March 27, 2002 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) today announced its results for the year ended Dec. 31, 2001 and an update on its restructuring plan.
Key events...
CeNeS Signs Agreement to Assign its Head Office Lease
December 11, 2001 05:01 ET
|
CeNeS Pharmaceuticals Plc
CAMBRIDGE, U.K., Dec. 11, 2001 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) announced today that it had exchanged contracts to assign its head office lease at Compass House, Cambridge to De...
CeNeS Announces the Sale of its Chemical Library of Ion Channel Blockers to Scion Pharmaceuticals Inc. for up to $2.8 Million (with link)
November 29, 2001 02:22 ET
|
CeNeS Pharmaceuticals Plc
CAMBRIDGE, U.K., Nov. 29, 2001 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) announced today that it has signed an agreement to sell its chemical library of ion channel blockers to Scion...
CeNeS Signs AutoPatch Technology Agreement with Wyeth-Ayerst Research, a Division of American Home Products Corporation
November 14, 2001 02:43 ET
|
CeNeS Pharmaceuticals Plc
CAMBRIDGE, United Kingdom, Nov. 14, 2001 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) announced today that it had signed an agreement worth $1.2 million for the supply of its proprietary ion...
CeNeS Announces Restructuring Program Update (with link)
November 12, 2001 03:53 ET
|
CeNeS Pharmaceuticals Plc
CAMBRIDGE, UK, Nov. 12, 2001 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) today announced an update on the progress it has made in the group restructuring that was first announced on October 1,...
CeNeS Announces Termination of the Opiate Spray Agreements with Bioglan (with link)
October 30, 2001 12:37 ET
|
CeNeS Pharmaceuticals Plc
CAMBRIDGE, UK, Oct. 30, 2001 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) today announced that it is terminating the development and licence agreements it has with Bioglan Pharma Plc (LSE:BGP)...
CeNeS Reports 2001 Interim Results and Planned Restructuring
October 01, 2001 03:18 ET
|
CeNeS Pharmaceuticals Plc
CAMBRIDGE, UK, Oct. 1, 2001 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) today announced its unaudited interim financial results for the six months ended June 30, 2001 and a planned...
CeNeS Announces Strategic Alliance with Cardinal Health Subsidiary, IPC (International Processing Corp.) (with link)
September 17, 2001 02:29 ET
|
CeNeS Pharmaceuticals Plc
CAMBRIDGE, UK, Sept. 16, 2001 (PRIMEZONE) -- CeNeS Pharmaceuticals Plc (LSE:CEN) today announced that it's drug delivery division, based in Scotland, has signed a strategic alliance with...